ABSTRACT:
As the aerosol delivery of liposome encapsulated drug to lower respiratory tract provides an effective therapy in various pulmonary diseases and disorders, we prepared liposomal nebulising solutions of antiasthmatic drug, salbutamol sulphate. Nebulisers of salbutamol sulphate are useful for giving high doses of medication in severe life threatening asthma. Asthma medication should be at least 80% vapourised within about 8minutes when administered through nebulisiers. The main objective was to study in vitro deposition pattern and maximum respirable fraction of drug of aerodynamic diameter reaching pulmonary region. About 50% of salbutamol sulphate was entrapped in liposomes with mass balance 99.39% and vesicle size was found optimum as 1-3µm. The marketed conventional nebulising solution of salbutamol showed comparatively less Net Respirable Fraction and more deposition in the upper respiratory tract as compared to the liposomal preparations.The release was extended for almost 10 hrs from the liposomes.